MedTrace Logo

Clinical Study of Stage IV Psoriasis in Children With Geleli

NCT05803187 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-03-13

No results posted yet for this study

Summary

This study is a multicenter, prospective, observational phase IV clinical study. A total of 80 children and adolescents with severe plaque psoriasis were included in the study. The study is expected to last for 24 weeks (169 days). This study will evaluate the efficacy and safety of Valerie ® (Adalimumab Injection) in Chinese children over 4 years old and adolescents with severe plaque psoriasis.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Jun Gu, Senior · Shanghai 10th People's Hospital

Eligibility

Min Age
4 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-05
Primary Completion
2025-03-30
Completion
2025-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05803187 on ClinicalTrials.gov